MiNK Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
MiNK Therapeutics, Inc. (INKT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 64.29 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 64.29K shares.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 117.48K shares.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 121.65K shares, a 43.18% decline from fiscal 2024.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 214.09K shares, a 78.65% decline from fiscal 2023.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.00M shares, a 51.79% decline from fiscal 2022.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.08M shares, a 7.12% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 64.29K shares 10-Q · filed 2026-08-13 | 181.77K shares derived: sum of 3 quarters · filed 2026-08-13 | 181.77K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 64.29K shares 10-Q · filed 2026-05-15 | 181.77K shares derived: sum of 2 quarters · filed 2026-05-15 | 181.77K shares derived: sum of 3 quarters · filed 2026-05-15 | 185.94K shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 117.48K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 117.48K shares derived: sum of 2 quarters · filed 2026-03-31 | 121.65K shares derived: sum of 3 quarters · filed 2026-03-31 | 121.65K shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 4.17K shares derived: sum of 2 quarters · filed 2025-11-14 | 4.17K shares 10-Q · filed 2025-11-14 | -1.92M shares derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | 4.17K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 4.17K shares 10-Q · filed 2025-08-14 | -1.92M shares derived: sum of 3 quarters · filed 2025-08-14 | -1.92M shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-15 | -1.93M shares derived: sum of 2 quarters · filed 2025-05-15 | -1.93M shares derived: sum of 3 quarters · filed 2025-05-15 | -1.13M shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | -1.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -1.93M shares derived: sum of 2 quarters · filed 2025-03-18 | -1.13M shares derived: sum of 3 quarters · filed 2025-03-18 | 214.09K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 793.88K shares derived: sum of 2 quarters · filed 2024-11-14 | 2.14M shares 10-Q · filed 2024-11-14 | 2.34M shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 793.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 2.14M shares 10-Q · filed 2024-08-13 | 2.34M shares derived: sum of 3 quarters · filed 2024-08-13 | 2.35M shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 1.35M shares 10-Q · filed 2024-05-14 | 1.55M shares derived: sum of 2 quarters · filed 2024-05-14 | 1.55M shares derived: sum of 3 quarters · filed 2024-05-14 | 1.70M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 200.21K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 205.47K shares derived: sum of 2 quarters · filed 2024-03-21 | 354.37K shares derived: sum of 3 quarters · filed 2024-03-21 | 1.00M shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 5.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 154.16K shares derived: sum of 2 quarters · filed 2023-11-14 | 802.53K shares 10-Q · filed 2023-11-14 | 822.53K shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | 148.91K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 797.28K shares 10-Q · filed 2023-08-10 | 817.28K shares derived: sum of 3 quarters · filed 2023-08-10 | 817.28K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 648.37K shares 10-Q · filed 2023-05-11 | 668.37K shares derived: sum of 2 quarters · filed 2023-05-11 | 668.37K shares derived: sum of 3 quarters · filed 2023-05-11 | 668.37K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 20.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | 20.00K shares derived: sum of 2 quarters · filed 2023-03-24 | 20.00K shares derived: sum of 3 quarters · filed 2023-03-24 | 2.08M shares 10-K · filed 2023-03-24 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-03 | 2.06M shares 10-Q · filed 2022-11-03 | 2.06M shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 2.06M shares 10-Q · filed 2022-08-15 | 2.06M shares derived: sum of 3 quarters · filed 2022-08-15 | |
| 2022-03-31 | 2.06M shares 10-Q · filed 2022-05-13 | 2.06M shares derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2021-12-31 | -7.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | 2.24M shares 10-K · filed 2022-03-18 | ||
| 2021-09-30 | 2.24M shares 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |